Wound Care Biologics Market is expanding rapidly as Organogenesis Holdings Inc. launches advanced wound care innovations including PuraPly AM, NuShield, Apligraf, and Affinity

 

Wound Care Biologics is scientifically designed products that are utilized for remedying non-healing wounds without affecting the body's natural repair processes. It also involves the application of specific active pharmaceutical proteins like different plant-based active proteins that exhibit super antibody and cell-penetrating abilities. One of the primary applications of wound care biologics in severe injuries occurred during burn incidents or road accidents. As per the World Health Organization (WHO), every year, around 1.35 million people die due to road traffic crash, while 50 million suffer from non-fatal injuries and many suffer a disability. Wound care biologics are intended to provide reestablishment of the essential repair mechanism. Thus, such factors can augment growth of the wound care biologics market.

Another key factor that could govern the development of the Wound Care Biologics Market is rapidly growing geriatric population. Elderly people are most likely to suffer from injuries and would require advanced wound care treatment. The trend of growing geriatric population has been observed in both developed and emerging economies and thus, the demand for biologics is likely to surge. Hence, these factors can stimulate growth of the wound care biologics market. Recently, in May 2021, Organogenesis Holdings Inc., a U.S.-based regenerative medicine company, launched advanced wound care innovations including PuraPly AM, NuShield, Apligraf, and Affinity.

The demand in the diabetic patients market for wound care biologics is high and the manufacturers are facing stiff competition from each other. With this situation, the quality of ingredients used in the formulation of these products has been a matter of great debate. Recent studies suggest that the use of high-quality ingredients in wound care biologics provides excellent results in diabetic patients. According to these studies, diabetic patients who had access to high-quality wound care biologics were found to recover better from their wounds. When it comes to geographical segmentation, North America seems to be gaining significant traction in the Wound Care Biologics Market. This is typically due to rapidly growing diabetic population and increasing cases of burn injuries. On the contrary, Asia Pacific is exhibiting positive signs due to rising geriatric population and improving the healthcare sector.

One of the major challenges faced by healthcare providers and system owners around the world is the high cost of caring for patients with chronic diseases. Improving the quality of diabetic products, especially in the area of wound care and integration of precision technology is the primary objective of the company. That being said, there is a risk associated with skin substitute failure, which would dissuade consumers to adopt wound care biologics. Besides, the high cost involved in wound treatment, especially in the case of chronic wounds, can potentially impede growth of the wound care biologics market in the near future.